Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

• ClinicalTrials.gov Identifier: NCT01587352
• Recruitment Status: Active, not recruiting
• First Posted: April 30, 2012
• Last Update Posted: February 16, 2023
• Sponsor: National Cancer Institute (NCI)
• Collaborators: Institut Curie Paris; Memorial Sloan Kettering Cancer Center; Moffitt Cancer Center P2C
• Information provided by (Responsible Party): National Cancer Institute (NCI)

Study Description

Brief Summary:

This phase II trial studies how well vorinostat works in treating patients with melanoma of the eye that has spread to other parts of the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Condition or disease	Intervention/treatment	Phase
Metastatic Uveal Melanoma; Stage IV Uveal Melanoma AJCC v7	Other: Laboratory Biomarker Analysis; Drug: Vorinostat	Phase 2

Detailed Description:

PRIMARY OBJECTIVE:

I. To determine the overall objective response rate (RR) to vorinostat in patients with metastatic uveal melanoma.

SECONDARY OBJECTIVES:

I. Overall survival (OS). II. Progression free survival (PFS). III. To determine the tolerability of vorinostat in patients with metastatic uveal melanoma.

EXPLORATORY OBJECTIVES:

I. To correlate clinical outcome with changes in histone acetylation status by immunohistochemistry.

II. To correlate clinical outcome with changes in known proliferation and apoptotic markers including Ki67 by immunohistochemistry and BIM, survivin, c-myc, Mcl-1, cleaved PARP, gamma-H2AX and RAD51 by western blot.

III. To assess for changes in pathways such as the MAPK pathway with treatment. IV. To describe the evolution of circulating cell-free, tumor-derived deoxyribonucleic acid (DNA) levels measured by pyrophosphorolysis activated polymerization (PAP) in plasma of patients under treatment for metastatic uveal melanoma.

V. To correlate overall objective RR with GNAQ, GNA11, SF3B1 and BAP1 mutational status.

OUTLINE:

Patients receive vorinostat orally (PO) twice daily (BID) for 3 days weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 12 weeks.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 40 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
• Actual Study Start Date: April 20, 2012
• Estimated Primary Completion Date: December 31, 2023
• Estimated Study Completion Date: December 31, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Treatment (vorinostat); Patients receive vorinostat PO BID for 3 days weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Other: Laboratory Biomarker Analysis; Correlative studies; Drug: Vorinostat; Given PO; Other Names: L-001079038; MSK-390; SAHA; Suberanilohydroxamic Acid; Suberoylanilide Hydroxamic Acid; Zolinza

Outcome Measures

Primary Outcome Measures :

1. Overall response rate in patients with uveal melanoma [ Time Frame: Up to 3 years ]
   Defined as the rate of complete and partial responses. The response rate along with 90% confidence interval will be estimated.

Secondary Outcome Measures :

1. Overall survival [ Time Frame: From start of treatment to death or last follow-up will be estimated, assessed up to 3 years ]
   Overall survival curves will be generated using Kaplan-Meier methodology.
2. Progression free survival [ Time Frame: From start of treatment to date of progression, death or last follow-up will be estimated, assessed up to 3 years ]
   Progression-free survival curves will be generated using Kaplan-Meier methodology.
3. Incidence of toxicities [ Time Frame: Up to 3 years ]
   Assessed by National Cancer Institute Common Toxicity Criteria 4.0. Toxicity will be reported by type, frequency and severity.

Other Outcome Measures:

1. Gnaq mutation status [ Time Frame: Up to day 15 ]
   Associations of each unique mutation status with overall response will be assessed using Fisher's exact test.
2. GNA11 mutation status [ Time Frame: Up to day 15 ]
   Associations of each unique mutation status with overall response will be assessed using Fisher's exact test.
3. BAP1 mutation status [ Time Frame: Up to day 15 ]
   Associations of each unique mutation status with overall response will be assessed using Fisher's exact test.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients must have metastatic histologically or cytologically confirmed uveal melanoma. (If histologic or cytologic confirmation of the primary is not available, confirmation of the primary diagnosis of uveal melanoma by the treating investigator can be clinically obtained, as per standard practice for uveal melanoma). Pathologic confirmation of diagnosis will be performed at Columbia University, Memorial Sloan-Kettering Cancer Center (MSKCC) or Vanderbilt University Medical Center
• Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
• Age >= 18 years. Because limited dosing or adverse event data are currently available on the use of vorinostat in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric single-agent trials, if applicable
• Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
• Life expectancy of greater than 3 months
• Leukocytes >= 3,000/mcL
• Absolute neutrophil count >= 1,500/mcL
• Platelets >= 100,000/mcL
• Hemoglobin >= 9.0 g/dL not requiring transfusions within the past 2 weeks
• Total bilirubin =< 1.5 x institutional upper limit of normal (ULN); =< 3 x institutional ULN if the patient has Gilbert's syndrome
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN if no liver metastasis present; =< 5 x institutional ULN if liver metastases are present
• Creatinine =< 1.5 mg/dL
• Ability to understand and the willingness to sign a written informed consent document
• Vorinostat is toxic to the developing human fetus. For this reason and because Class D agents are known to be teratogenic, women of child-bearing potential and men must agree to use effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of vorinostat administration

Exclusion Criteria:

• Patients may have had any number of prior therapies. At least 3 weeks must have elapsed since the last dose of systemic therapy. At least 6 weeks must have elapsed if the last regimen included BCNU or mitomycin C. At least 6 weeks must have elapsed if the last regimen included an anti-CTLA4 antibody. Patients must have experienced disease progression on their prior therapy in the opinion of the treating investigator
• Patients who are receiving any other investigational agents
• Patients with active or untreated brain metastases. Treated brain metastases must have been stable for at least 2 months
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat
• Patients receiving HDAC inhibitors or compounds with HDAC inhibitor like activity, such as valproic acid, are ineligible. Patients who have received such agents may enroll on this study after a 14-day washout period
• Patients on warfarin will be excluded from the trial if they cannot be switched to an acceptable alternative medication (i.e. low molecular weight heparin [LMWH]). Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving vorinostat concomitantly with coumarin-derivative anticoagulants
• Pregnant women are excluded from this study because vorinostat is a Class D agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vorinostat, breastfeeding should be discontinued if the mother is treated with vorinostat
• Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy will be eligible unless the CD4 count is < 200 cells/mm^3 within one month of study enrollment (as requested by Cancer Therapy Evaluation Program [CTEP]). These patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
• A second malignancy requiring active therapy
• No concomitant anti-cancer chemotherapy or other systemic drugs. Palliative radiation therapy will be allowed as long as the patient meets all other eligibility criteria
• Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption
• Corrected QT interval (QTc) > 475 milliseconds
• Patients who cannot swallow capsules

Contacts and Locations

Locations

United States, New York

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, United States, 10032

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

United States, Tennessee

Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, United States, 37232

Sponsors and Collaborators

National Cancer Institute (NCI)

Institut Curie Paris

Memorial Sloan Kettering Cancer Center

Moffitt Cancer Center P2C

Investigators

• Principal Investigator: Alexander N Shoushtari; Memorial Sloan Kettering Cancer Center

More Information

• Responsible Party: National Cancer Institute (NCI)
• ClinicalTrials.gov Identifier: NCT01587352
• Other Study ID Numbers: NCI-2012-00860; NCI-2012-00860 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); CUMC-IRBAAAO5917; AAAO5917; MSKCC-12-027; AAAO5917 ( Other Identifier: Memorial Sloan Kettering Cancer Center ); 9111 ( Other Identifier: CTEP ); N01CM00100 ( U.S. NIH Grant/Contract ); N01CM62206 ( U.S. NIH Grant/Contract ); P30CA008748 ( U.S. NIH Grant/Contract ); U01CA069856 ( U.S. NIH Grant/Contract ); UM1CA186689 ( U.S. NIH Grant/Contract )
• First Posted: April 30, 2012
• Last Update Posted: February 16, 2023
• Last Verified: February 2023

Additional relevant MeSH terms:

Melanoma; Uveal Neoplasms; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Eye Neoplasms; Neoplasms by Site; Eye Diseases; Uveal Diseases; Vorinostat; Antineoplastic Agents; Histone Deacetylase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action